-

Sera Prognostics to Present at the 38th Annual JP Morgan Healthcare Conference

SALT LAKE CITY--(BUSINESS WIRE)--Sera Prognostics, Inc., the leading health diagnostics company dedicated to improving the lives of women and babies through individualized prenatal care, will be presenting at the upcoming JP Morgan 2020 Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday, January 15th, at 3:30 p.m. PT.

Gregory C. Critchfield, M.D., M.S., Chairman and CEO, will discuss Sera’s latest achievements and upcoming clinical data read-outs.

Sera’s management will be available for one-on-one meetings with conference attendees after the presentation.

About Sera Prognostics, Inc.

Sera Prognostics is the leading health diagnostics company dedicated to improve the lives of women and babies through individualized prenatal care. Sera delivers pivotal information to physicians to improve health and to improve the economics of healthcare delivery for pregnant women. Sera is developing innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® test objectively reports to a physician the risk of a woman’s premature delivery, enabling earlier proactive interventions designed to improve the health of her baby. Sera is working with other researchers to demonstrate the impact of additional interventions to improve pregnancy outcomes when used in connection with the PreTRM® test to stratify risk of prematurity. Sera Prognostics is located in Salt Lake City, Utah. For more information, please visit the company’s website at www.seraprognostics.com.

About the PreTRM® Test

The PreTRM® test is the only clinically-validated blood test that provides an early and individual risk prediction for spontaneous preterm birth in asymptomatic, singleton pregnancies. The PreTRM® test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM® test can help physicians identify early in the pregnancy (as early as 19 weeks of gestation) which women are at increased risk for premature delivery, enabling more informed clinical decisions based on each woman’s individual risk. The PreTRM® test is ordered by a medical professional. For more information about the PreTRM® test, please visit www.PreTRM.com and the PreTRM® test YouTube Channel. You can also join the conversation on Facebook and @PreTRM.

Contacts

Andrew Sauter, CFO
Sera Prognostics, Inc.
info@seraprognostics.com
(801) 990-0772

Industry:

Sera Prognostics, Inc.

Release Versions
English

Contacts

Andrew Sauter, CFO
Sera Prognostics, Inc.
info@seraprognostics.com
(801) 990-0772

More News From Sera Prognostics, Inc.

Data Confirming Performance of Sera Prognostic’s PreTRM® Test Predictor in an Independent Large Cohort and Testing Enhancements to be Presented at the Society for Maternal-Fetal Medicine’s 40th Annual Pregnancy Meeting

SALT LAKE CITY--(BUSINESS WIRE)--Sera Prognostics, Inc., the leading women’s precision pregnancy company, today, announced two podium presentations to take place at the Society for Maternal-Fetal Medicine’s 40th Annual Pregnancy Meeting in Grapevine, Texas, near Dallas, on February 3-8, 2020. The following presentations will highlight the performance of Sera’s innovative PreTRM® biomarker testing approach: Abstract #9: Performance of a proteomic preterm delivery predictor in a large independent...

Sera Prognostics Announces Completion of Important Prevent PTB Clinical Intervention Study Using the PreTRM® Test

SALT LAKE CITY--(BUSINESS WIRE)--Sera Prognostics, Inc., the leading health diagnostics company dedicated to improve the lives of women and babies through individualized prenatal care, today, announced that the Prevent PTB clinical study conducted by Intermountain Healthcare is being prepared for publication in a peer-reviewed scientific journal. This study is the first of its kind to measure the impact on maternal and neonatal health and healthcare costs when standard medical interventions are...
Back to Newsroom